Logo image of HALO

HALOZYME THERAPEUTICS INC (HALO) Stock Fundamental Analysis

NASDAQ:HALO - Nasdaq - US40637H1095 - Common Stock - Currency: USD

56.58  -0.06 (-0.11%)

Fundamental Rating

7

Taking everything into account, HALO scores 7 out of 10 in our fundamental rating. HALO was compared to 572 industry peers in the Biotechnology industry. HALO gets an excellent profitability rating and is at the same time showing great financial health properties. HALO is evaluated to be cheap and growing strongly. This does not happen too often! This makes HALO very considerable for value and growth and quality investing!


Dividend Valuation Growth Profitability Health

Quickly go to:

7

1. Profitability

1.1 Basic Checks

HALO had positive earnings in the past year.
HALO had a positive operating cash flow in the past year.
Of the past 5 years HALO 4 years were profitable.
Of the past 5 years HALO 4 years had a positive operating cash flow.
HALO Yearly Net Income VS EBIT VS OCF VS FCFHALO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M -100M 200M 300M 400M

1.2 Ratios

HALO's Return On Assets of 18.53% is amongst the best of the industry. HALO outperforms 98.58% of its industry peers.
With an excellent Return On Equity value of 86.69%, HALO belongs to the best of the industry, outperforming 99.65% of the companies in the same industry.
With an excellent Return On Invested Capital value of 19.23%, HALO belongs to the best of the industry, outperforming 98.05% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for HALO is above the industry average of 13.85%.
The 3 year average ROIC (17.78%) for HALO is below the current ROIC(19.23%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 18.53%
ROE 86.69%
ROIC 19.23%
ROA(3y)21.23%
ROA(5y)14.64%
ROE(3y)219.81%
ROE(5y)133.26%
ROIC(3y)17.78%
ROIC(5y)N/A
HALO Yearly ROA, ROE, ROICHALO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100 200 300

1.3 Margins

HALO's Profit Margin of 41.43% is amongst the best of the industry. HALO outperforms 98.76% of its industry peers.
In the last couple of years the Profit Margin of HALO has declined.
With an excellent Operating Margin value of 50.35%, HALO belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
In the last couple of years the Operating Margin of HALO has declined.
HALO's Gross Margin of 82.09% is amongst the best of the industry. HALO outperforms 87.26% of its industry peers.
In the last couple of years the Gross Margin of HALO has declined.
Industry RankSector Rank
OM 50.35%
PM (TTM) 41.43%
GM 82.09%
OM growth 3Y-8.72%
OM growth 5YN/A
PM growth 3Y-11.05%
PM growth 5YN/A
GM growth 3Y-2.86%
GM growth 5Y-3.81%
HALO Yearly Profit, Operating, Gross MarginsHALO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50 -50

More info and screens

7

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), HALO is creating value.
Compared to 1 year ago, HALO has less shares outstanding
HALO has less shares outstanding than it did 5 years ago.
Compared to 1 year ago, HALO has a worse debt to assets ratio.
HALO Yearly Shares OutstandingHALO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M
HALO Yearly Total Debt VS Total AssetsHALO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 500M 1B 1.5B

2.2 Solvency

HALO has an Altman-Z score of 4.63. This indicates that HALO is financially healthy and has little risk of bankruptcy at the moment.
With a decent Altman-Z score value of 4.63, HALO is doing good in the industry, outperforming 79.65% of the companies in the same industry.
The Debt to FCF ratio of HALO is 3.83, which is a good value as it means it would take HALO, 3.83 years of fcf income to pay off all of its debts.
HALO has a Debt to FCF ratio of 3.83. This is amongst the best in the industry. HALO outperforms 94.16% of its industry peers.
HALO has a Debt/Equity ratio of 3.32. This is a high value indicating a heavy dependency on external financing.
With a Debt to Equity ratio value of 3.32, HALO is not doing good in the industry: 83.89% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 3.32
Debt/FCF 3.83
Altman-Z 4.63
ROIC/WACC1.95
WACC9.85%
HALO Yearly LT Debt VS Equity VS FCFHALO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 500M 1B

2.3 Liquidity

A Current Ratio of 10.36 indicates that HALO has no problem at all paying its short term obligations.
HALO has a Current ratio of 10.36. This is amongst the best in the industry. HALO outperforms 81.77% of its industry peers.
A Quick Ratio of 9.15 indicates that HALO has no problem at all paying its short term obligations.
HALO has a better Quick ratio (9.15) than 77.52% of its industry peers.
Industry RankSector Rank
Current Ratio 10.36
Quick Ratio 9.15
HALO Yearly Current Assets VS Current LiabilitesHALO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M

More info and screens

9

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 55.33% over the past year.
Measured over the past years, HALO shows a very strong growth in Earnings Per Share. The EPS has been growing by 45.64% on average per year.
The Revenue has grown by 21.36% in the past year. This is a very strong growth!
Measured over the past years, HALO shows a very strong growth in Revenue. The Revenue has been growing by 40.42% on average per year.
EPS 1Y (TTM)55.33%
EPS 3Y45.64%
EPS 5YN/A
EPS Q2Q%69.33%
Revenue 1Y (TTM)21.36%
Revenue growth 3Y45.79%
Revenue growth 5Y40.42%
Sales Q2Q%34.28%

3.2 Future

The Earnings Per Share is expected to grow by 27.06% on average over the next years. This is a very strong growth
HALO is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 17.06% yearly.
EPS Next Y51.47%
EPS Next 2Y36.14%
EPS Next 3Y33.85%
EPS Next 5Y27.06%
Revenue Next Year20.86%
Revenue Next 2Y19.5%
Revenue Next 3Y20.84%
Revenue Next 5Y17.06%

3.3 Evolution

Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
HALO Yearly Revenue VS EstimatesHALO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B
HALO Yearly EPS VS EstimatesHALO Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 4 6 8

More info and screens

9

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 14.93 indicates a correct valuation of HALO.
Based on the Price/Earnings ratio, HALO is valued cheaper than 96.81% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 28.46, HALO is valued a bit cheaper.
A Price/Forward Earnings ratio of 10.98 indicates a reasonable valuation of HALO.
Based on the Price/Forward Earnings ratio, HALO is valued cheaply inside the industry as 97.52% of the companies are valued more expensively.
The average S&P500 Price/Forward Earnings ratio is at 92.87. HALO is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 14.93
Fwd PE 10.98
HALO Price Earnings VS Forward Price EarningsHALO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of HALO indicates a rather cheap valuation: HALO is cheaper than 96.64% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, HALO is valued cheaper than 96.81% of the companies in the same industry.
Industry RankSector Rank
P/FCF 18.33
EV/EBITDA 13.48
HALO Per share dataHALO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
HALO has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as HALO's earnings are expected to grow with 33.85% in the coming years.
PEG (NY)0.29
PEG (5Y)N/A
EPS Next 2Y36.14%
EPS Next 3Y33.85%

More info and screens

0

5. Dividend

5.1 Amount

HALO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

HALOZYME THERAPEUTICS INC

NASDAQ:HALO (2/3/2025, 2:45:07 PM)

56.58

-0.06 (-0.11%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-31 2024-10-31/amc
Earnings (Next)02-25 2025-02-25/amc
Inst Owners99.18%
Inst Owner Change-0.92%
Ins Owners0.97%
Ins Owner Change-0.3%
Market Cap7.20B
Analysts76
Price Target66.05 (16.74%)
Short Float %7.55%
Short Ratio5.24
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)22.23%
Min EPS beat(2)17.68%
Max EPS beat(2)26.79%
EPS beat(4)3
Avg EPS beat(4)13.34%
Min EPS beat(4)-2.55%
Max EPS beat(4)26.79%
EPS beat(8)6
Avg EPS beat(8)8.78%
EPS beat(12)9
Avg EPS beat(12)9.22%
EPS beat(16)12
Avg EPS beat(16)11.41%
Revenue beat(2)2
Avg Revenue beat(2)11.98%
Min Revenue beat(2)10.67%
Max Revenue beat(2)13.28%
Revenue beat(4)2
Avg Revenue beat(4)4.41%
Min Revenue beat(4)-3.87%
Max Revenue beat(4)13.28%
Revenue beat(8)3
Avg Revenue beat(8)0.91%
Revenue beat(12)5
Avg Revenue beat(12)0.96%
Revenue beat(16)8
Avg Revenue beat(16)3.1%
PT rev (1m)0.97%
PT rev (3m)5.28%
EPS NQ rev (1m)-1.42%
EPS NQ rev (3m)-4.66%
EPS NY rev (1m)-0.43%
EPS NY rev (3m)4.21%
Revenue NQ rev (1m)-0.92%
Revenue NQ rev (3m)1.35%
Revenue NY rev (1m)0.1%
Revenue NY rev (3m)1.99%
Valuation
Industry RankSector Rank
PE 14.93
Fwd PE 10.98
P/S 7.6
P/FCF 18.33
P/OCF 17.86
P/B 15.9
P/tB N/A
EV/EBITDA 13.48
EPS(TTM)3.79
EY6.7%
EPS(NY)5.15
Fwd EY9.11%
FCF(TTM)3.09
FCFY5.46%
OCF(TTM)3.17
OCFY5.6%
SpS7.45
BVpS3.56
TBVpS-3.02
PEG (NY)0.29
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 18.53%
ROE 86.69%
ROCE 23.74%
ROIC 19.23%
ROICexc 28.78%
ROICexgc 76.3%
OM 50.35%
PM (TTM) 41.43%
GM 82.09%
FCFM 41.46%
ROA(3y)21.23%
ROA(5y)14.64%
ROE(3y)219.81%
ROE(5y)133.26%
ROIC(3y)17.78%
ROIC(5y)N/A
ROICexc(3y)43.19%
ROICexc(5y)N/A
ROICexgc(3y)73.41%
ROICexgc(5y)N/A
ROCE(3y)21.95%
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-8.72%
OM growth 5YN/A
PM growth 3Y-11.05%
PM growth 5YN/A
GM growth 3Y-2.86%
GM growth 5Y-3.81%
F-Score9
Asset Turnover0.45
Health
Industry RankSector Rank
Debt/Equity 3.32
Debt/FCF 3.83
Debt/EBITDA 2.69
Cap/Depr 12.55%
Cap/Sales 1.08%
Interest Coverage 250
Cash Conversion 72.14%
Profit Quality 100.07%
Current Ratio 10.36
Quick Ratio 9.15
Altman-Z 4.63
F-Score9
WACC9.85%
ROIC/WACC1.95
Cap/Depr(3y)25.9%
Cap/Depr(5y)50.2%
Cap/Sales(3y)0.97%
Cap/Sales(5y)1.18%
Profit Quality(3y)107.65%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)55.33%
EPS 3Y45.64%
EPS 5YN/A
EPS Q2Q%69.33%
EPS Next Y51.47%
EPS Next 2Y36.14%
EPS Next 3Y33.85%
EPS Next 5Y27.06%
Revenue 1Y (TTM)21.36%
Revenue growth 3Y45.79%
Revenue growth 5Y40.42%
Sales Q2Q%34.28%
Revenue Next Year20.86%
Revenue Next 2Y19.5%
Revenue Next 3Y20.84%
Revenue Next 5Y17.06%
EBIT growth 1Y51.43%
EBIT growth 3Y33.08%
EBIT growth 5YN/A
EBIT Next Year72.48%
EBIT Next 3Y42.71%
EBIT Next 5Y27.27%
FCF growth 1Y65.36%
FCF growth 3Y91.68%
FCF growth 5YN/A
OCF growth 1Y67.76%
OCF growth 3Y91.3%
OCF growth 5YN/A